Videos

Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia: deutetrabenazine and valbenazine. Nurse Hoberg provides details on their mechanisms of action, contraindications, and side effects—all important considerations when helping patients find the best medication option for their treatment. For more expert insights on the disorder, visit the Tardive Dyskinesia Excellence Forum.

In this video, Rakesh Jain, MD, MPH, a distinguished member of the Psych Congress steering committee, details the concept of de-prescribing in psychiatry. Whether preparing for the possible need to adjust medication regimes, or helping patients stop treatment that is no longer needed, “Never, ever enter a war or a battle without an exit plan,” says Dr Jain.